SI2032521T1 - Nov postopek za pripravo soli - Google Patents

Nov postopek za pripravo soli

Info

Publication number
SI2032521T1
SI2032521T1 SI200730132T SI200730132T SI2032521T1 SI 2032521 T1 SI2032521 T1 SI 2032521T1 SI 200730132 T SI200730132 T SI 200730132T SI 200730132 T SI200730132 T SI 200730132T SI 2032521 T1 SI2032521 T1 SI 2032521T1
Authority
SI
Slovenia
Prior art keywords
new method
salt preparation
preparation
trialkylsilylhalogenide
hydroiodides
Prior art date
Application number
SI200730132T
Other languages
English (en)
Inventor
Josef Wieser
Hannes Lengauer
Elfriede Klingler
Arthur Pichler
Hubert Sturm
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37450796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2032521(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SI2032521T1 publication Critical patent/SI2032521T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Seasonings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SI200730132T 2006-06-27 2007-06-25 Nov postopek za pripravo soli SI2032521T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116134 2006-06-27
EP07785845A EP2032521B1 (en) 2006-06-27 2007-06-25 New method for salt preparation

Publications (1)

Publication Number Publication Date
SI2032521T1 true SI2032521T1 (sl) 2010-02-26

Family

ID=37450796

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730132T SI2032521T1 (sl) 2006-06-27 2007-06-25 Nov postopek za pripravo soli

Country Status (14)

Country Link
US (1) US20100204470A1 (sl)
EP (3) EP2032521B1 (sl)
JP (1) JP2009541385A (sl)
CN (1) CN101484411A (sl)
AT (1) ATE446946T1 (sl)
AU (1) AU2007264030B2 (sl)
CA (1) CA2655061A1 (sl)
DE (1) DE602007003024D1 (sl)
DK (1) DK2032521T3 (sl)
ES (1) ES2335369T3 (sl)
PL (1) PL2032521T3 (sl)
RU (1) RU2461542C2 (sl)
SI (1) SI2032521T1 (sl)
WO (1) WO2008000418A2 (sl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524735B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20100113793A1 (en) * 2006-03-20 2010-05-06 Ind-Swift Laboratories Limited Process for the Preparation of Highly Pure Donepezil
WO2008130630A2 (en) * 2007-04-16 2008-10-30 Teva Pharmaceutical Industries Ltd. Polymorphic form of rimonabant hydrochloride and processes for preparation thereof
EP2176241B1 (en) * 2007-08-17 2015-12-23 Hetero Drugs Limited A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
EP2257556A1 (en) 2008-02-06 2010-12-08 Helm AG Prasugrel salts with improved properties
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
PL2344129T3 (pl) 2008-10-07 2018-07-31 Horizon Orphan Llc Formulacje fluorochinolonu w aerozolu dla poprawy właściwości farmakokinetycznych
JP2012505222A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 肺炎症を低減するためのレボフロキサシンの吸入
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
US8772488B2 (en) 2009-03-31 2014-07-08 Shanghai Institute Of Pharmaceutical Industry Crystals of prasugrel hydrobromate
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
CZ2009828A3 (cs) 2009-12-09 2011-06-22 Zentiva, K.S. Zpusob prípravy hydrochloridu 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu hydrochloridu) v polymorfní forme B
PL2448945T3 (pl) 2010-04-08 2015-06-30 Teva Pharma Krystaliczne postacie soli prasugrelu
CN102212071B (zh) * 2010-04-08 2014-03-26 上海医药工业研究院 普拉格雷盐酸盐乙酸溶剂合物及其结晶和制备方法
CN102342921B (zh) * 2010-08-01 2013-09-11 江苏正大天晴药业股份有限公司 普拉格雷氢溴酸盐醋酸合物的药物组合物
EP2447256A1 (en) * 2010-10-21 2012-05-02 Laboratorios Lesvi, S.L. Process for obtaining dronedarone
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
US9108972B2 (en) 2011-03-03 2015-08-18 Cadila Healthcare Limited Salts of DPP-IV inhibitor
EA029539B8 (ru) * 2011-03-29 2018-06-29 Крка, Товарна Здравил, Д.Д., Ново Место Фармацевтическая композиция ситаглиптина
KR101766835B1 (ko) 2011-05-04 2017-08-09 에스프린팅솔루션 주식회사 화상형성장치 및 그 제어 방법
AU2012277373A1 (en) 2011-06-29 2014-01-30 Sun Pharmaceutical Industries Limited Solid dispersions of sitagliptin and processes for their preparation
CA2840806A1 (en) 2011-06-30 2013-01-03 Ranbaxy Laboratories Limited Novel salts of sitagliptin
WO2013084210A1 (en) 2011-12-08 2013-06-13 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts
EP2882291B1 (en) * 2012-08-07 2017-09-27 ZCL Chemicals Ltd. An improved process for the preparation of memantine hydrochloride
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process
CN103012427B (zh) * 2012-11-26 2015-07-08 天津大学 一种普拉格雷盐酸盐乙醇溶剂化物及其制备方法
PL402028A1 (pl) 2012-12-12 2014-06-23 Instytut Farmaceutyczny Sposób wytwarzania postaci polimorficznej B chlorowodorku prasugrelu o czystości farmaceutycznej
CN103739500B (zh) * 2012-12-27 2016-03-23 国药一心制药有限公司 一种盐酸西那卡塞的合成与精制方法
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
IN2013MU00665A (sl) * 2013-03-05 2015-07-03 Cipla Ltd
CN103145628B (zh) * 2013-03-18 2015-04-22 齐鲁制药有限公司 一种厄洛替尼一水合物晶型i的制备方法
CN104072442B (zh) * 2013-03-28 2016-09-28 成都弘达药业有限公司 一种化合物及其制备方法
CN103396371B (zh) * 2013-08-26 2015-12-02 南京优科生物医药研究有限公司 一种盐酸埃罗替尼晶型a的制备方法
IN2014MU00651A (sl) 2014-02-25 2015-10-23 Cadila Healthcare Ltd
WO2015170340A2 (en) * 2014-05-06 2015-11-12 Laurus Labs Private Limited Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
CN107540632A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法
CN107540634A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法
JP2020535231A (ja) * 2017-09-26 2020-12-03 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規な塩および結晶
MX2020013182A (es) * 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.
EP3896063B1 (en) * 2018-12-14 2024-01-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline forms of the syk inhibitor 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salt (1:1)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU46919B (sh) * 1988-07-13 1994-06-24 Krka Tovarna Zdravil N.Sol.O. Postupak za dobijanje derivata l-alanil-l-prolina
TW209865B (sl) 1992-01-10 1993-07-21 Bayer Ag
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
JP3411038B2 (ja) 1993-09-15 2003-05-26 シンテックス（ユー・エス・エイ）・インコーポレイテッド ミコフェノール酸モフェチルの結晶質無水物およびその静注用製剤
DE19546249A1 (de) 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
AU731282B2 (en) 1996-06-07 2001-03-29 Eisai Co. Ltd. Polymorphs of donepezil hydrochloride and process for production
ATE213246T1 (de) 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CZ302990B6 (cs) * 2000-07-06 2012-02-08 Daiichi Sankyo Company, Limited Adicní soli derivátu hydropyridinu s kyselinou chlorovodíkovou a maleinovou, príprava a použití
CN1620420A (zh) 2000-10-19 2005-05-25 特瓦制药工业有限公司 结晶文拉法辛碱和新的文拉法辛盐酸盐多晶型物及其制备方法
CA2426393C (en) 2000-10-31 2012-05-29 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
KR100692934B1 (ko) * 2000-12-25 2007-03-12 상꾜 가부시키가이샤 아스피린을 함유하는 의약 조성물
DE10153345A1 (de) * 2001-10-29 2003-05-08 Gruenenthal Gmbh Substituierte 1H-Chinoxalin-2-on-Verbindungen und substituierte 4-Aryl- und 4-Heteroarylcyclohexan-Verbindungen
UA77234C2 (en) 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
DE10161818A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Substituierte 1,5-Diaminopentan-3-ol-Verbindungen
DE10261091A1 (de) * 2002-12-20 2004-07-01 Grünenthal GmbH Gesättigte und ungesättigte Heteroarylcycloalkylmethyl-Amine
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1606262A1 (en) 2003-03-21 2005-12-21 Hetero Drugs Limited Novel crystalline forms of aripiprazole
EP1660183A2 (en) * 2003-05-05 2006-05-31 Eli Lilly and Company Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4)
US20060264635A1 (en) * 2003-08-05 2006-11-23 Chava Satyanarayana Process for the preparation of moxifloxacin hydrochloride
DE602004018370D1 (de) 2003-11-20 2009-01-22 Chemi Spa Polymorphe von 1-cyclopropyl-7-(äs,sü - 2,8-diazadicyclo ä4.3.0ü non-8-yl) -6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäurehydrochlorid und verfahren zu deren herstellung
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
JP2008512417A (ja) * 2004-09-10 2008-04-24 ユセベ ファルマ ソシエテ アノニム シグマ受容体リガンド

Also Published As

Publication number Publication date
RU2461542C2 (ru) 2012-09-20
WO2008000418A3 (en) 2008-02-28
EP2145890B1 (en) 2012-08-01
DE602007003024D1 (de) 2009-12-10
PL2032521T3 (pl) 2010-05-31
CA2655061A1 (en) 2008-01-03
WO2008000418A2 (en) 2008-01-03
RU2009102279A (ru) 2010-08-10
ATE446946T1 (de) 2009-11-15
AU2007264030B2 (en) 2012-04-05
EP2032521B1 (en) 2009-10-28
EP2032521A2 (en) 2009-03-11
EP2145890A2 (en) 2010-01-20
US20100204470A1 (en) 2010-08-12
EP2145890A3 (en) 2010-03-31
CN101484411A (zh) 2009-07-15
JP2009541385A (ja) 2009-11-26
EP2436381A1 (en) 2012-04-04
DK2032521T3 (da) 2010-01-25
AU2007264030A1 (en) 2008-01-03
ES2335369T3 (es) 2010-03-25

Similar Documents

Publication Publication Date Title
PL2032521T3 (pl) Nowy sposób wytwarzania soli
ZA200704789B (en) Novel anthranilic acid derivative or salt thereof
EP2385053A3 (en) Intermediates for the preparation of fused bicyclic mTOR inhibitors
EP1860098A4 (en) NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT
TNSN07277A1 (en) Pharmaceutical compounds
IL182957A0 (en) Potentiators of glutamate receptors
IL178097A0 (en) Polymorphs of acid addition salts of iamatinib with methanesulfonic acid
WO2010125216A3 (es) Preparación de compuestos 5,6-dihidropirido[2,3-d]pirimidin-7(8h)-ona sustituidos
IL185244A0 (en) 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
IL205189A0 (en) Derivatives of 6, 7 - dihydro - 5h - imidazo (1, 2 -?? ) imidazole - 3 - carboxylic acid amides
WO2010129918A8 (en) Triptolide prodrugs
IL183591A0 (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
GEP20084494B (en) New heterocyclic carboxylic acid amide derivatives
ZA200804171B (en) Chemical process for the preparation of an amidophenoxybenzoic acid compound
BRPI0508430A (pt) processo para a preparação de inibidores da triptase
AP2007004270A0 (en) Process for preparing salts of hydrocyanic acid
HUP0402466A2 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process
HUP0402465A2 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main intermediates of the process
MA29092B1 (fr) Procédé de synthèse de salicylamides n-substitués
ZA200805701B (en) Salts of styphnic acid
WO2007063556A3 (en) An improved and industrial process for the preparation of alfuzosin hydrochloride and its novel polymorphs
IS7477A (is) Aðferð við framleiðslu sýrusalts af gemifloxasíni
EA200901229A1 (ru) Новый способ получения левоцетиризина и его промежуточных соединений
TW200740756A (en) Potentiator of glutamate receptors
TH87312A (th) สารประกอบเบนซิมิแดโซลไธโอฟีน